Moderna Inc. ($MRNA) Stock Forecast: Up 5.5% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, notably in the realm of COVID-19 vaccine development. Recently, the stock showed a notable upturn in the market.

Why is Moderna Inc. going up?

MRNA stock is up 5.5% on Apr 8, 2026 19:12

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna eyes international markets as growth driver, says Bank of America

Bank of America analysts expect Moderna to highlight its progress in international COVID-19 vaccine markets as a growth driver when it reports first quarter 2026 results. The analysts project international markets will contribute significantly, with agreements like the UK's COVID booster program and opening markets following pandemic-era agreements. Despite reducing RSV vaccine revenue projections, Bank of America increased COVID-19 revenue estimates and reiterated an 'Underperform' rating and $31 price target.

https://www.proactiveinvestors.com/companies/news/1090218/moderna-eyes-international-markets-as-growth-driver-says-bank-of-america-1090218.html

Cancer drug developer taps Guardant executive for regulator strategy

OS Therapies (NYSE:OSTX) has appointed Dr. Craig Eagle, former Guardant Health CMO, to its new strategic advisory board to guide regulatory execution for osteosarcoma and prioritize its oncology pipeline. Dr. Eagle brings extensive experience from Guardant Health, Genentech, and Pfizer, particularly in oncology therapeutic and biomarker development. This move aims to leverage his expertise to refine regulatory strategies based on Phase 2b biomarker insights and advance clinical-stage assets across various cancer indications.

https://www.stocktitan.net/news/OSTX/os-therapies-appoints-craig-eagle-md-as-strategic-3vnzy36pdyhg.html

Forte Biosciences Inc stock: What investors need to know in biotech volatility

Forte Biosciences Inc (NASDAQ: FBRX) is a clinical-stage biotech company focused on developing therapies for inflammatory diseases, leveraging proprietary platforms to modulate immune responses. While analyst coverage is limited due to its small size and clinical stage, its immunology innovation and pipeline progress could make it an interesting, albeit high-risk, play for global investors comfortable with the sector's volatility. Its potential lies in advancing clinical programs that could disrupt current standards in dermatology and gastroenterology, making pipeline updates key signals for investors.

https://www.ad-hoc-news.de/boerse/ueberblick/forte-biosciences-inc-stock-what-investors-need-to-know-in-biotech/69099498

Morgan Stanley raises AstraZeneca stock price target on pipeline progress

Morgan Stanley has increased its price target for AstraZeneca (NASDAQ:AZN) shares to $220 from $219, maintaining an Overweight rating, citing positive pipeline developments and foreign exchange updates. This adjustment comes ahead of AstraZeneca's first-quarter 2026 results, with Morgan Stanley forecasting sales and earnings per share slightly above consensus due to strong performance in Oncology and cardiovascular, renal, and metabolism products. The company also highlighted recent positive Phase III trial results for Imfinzi, Imjudo, efzimfotase alfa, and tozorakimab.

https://www.investing.com/news/analyst-ratings/morgan-stanley-raises-astrazeneca-stock-price-target-on-pipeline-progress-93CH-4601318

Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment

Pfizer (PFE) has initiated a new Phase 1 study for its experimental drug PF-07328948 to understand its pharmacokinetics in healthy adult men. The study, which is not yet recruiting, will evaluate oral liquid and tablet forms, including a radiolabeled version, to determine absorption, distribution, metabolism, and excretion. This early-stage research supports Pfizer's long-term pipeline development but is not expected to be a near-term catalyst for the company's stock.

https://www.tipranks.com/news/company-announcements/pfizers-new-phase-1-pf-07328948-study-signals-ongoing-pipeline-investment

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.3% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.5% Today

Mohawk Industries Inc. ($MHK) Stock Forecast: Down 5.3% Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 6.8% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Down 5.6% Today

Salesforce.com Inc ($CRM) Stock Forecast: Down 5.2% Today

Sonos Inc. ($SONO) Stock Forecast: Down 6.6% Today

Reddit Inc ($RDDT) Stock Forecast: Down 5.6% Today

Devon Energy Corporation ($DVN) Stock Forecast: Up 5.8% Today

Moderna Inc. Price History

02.03.2026 - MRNA Stock was down 5.2%

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

02.03.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement today, possibly influenced by:
• Pfizer and BioNTech halting enrollment in a large U.S. COVID-19 vaccine trial due to slow recruitment, reflecting potential challenges and decreased interest in vaccine trials.
• Market sentiment shifting towards Allogene Therapeutics, which is gaining momentum in the biotechnology sector with positive clinical pipeline developments, diverting attention from Moderna.
• Mixed trade ideas and technical analyses on Moderna's stock from traders, indicating uncertainty and varied perspectives on its future movements.
• The bearish trend in Moderna's stock today could be a result of concerns regarding vaccine trial enrollment, competition in the biotech sector, and divergent market analyses, leading to a decline in investor confidence in the short term.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

17.02.2026 - MRNA Stock was up 5.5%

• Today's positive movement in Moderna's stock price is linked to a recent federal court decision blocking proposed changes to the U.S. vaccine policy, a move by Health Secretary Robert F. Kennedy Jr. This ruling has provided stability for Moderna amidst concerns of policy changes impacting biotech revenues.
• Noteworthy insider selling by key individuals such as Moderna President Stephen Hoge, alongside decreased stake holdings by investment entities like Militia Capital Partners LP, contrasts the company's robust financial performance. With $1.9 billion in total revenue for 2025, investor trust in Moderna remains strong.
• The introduction of IQVIA.ai, an advanced AI platform developed in partnership with NVIDIA, to enhance operational efficiency and decision-making in the life sciences domain, may have positively influenced market sentiment towards forward-thinking biotech firms like Moderna.
• Criticism directed at the FDA for inconsistent actions, particularly concerning Moderna's vaccine submissions, underscores regulatory uncertainties that could impact the company's future initiatives and market dynamics. Nonetheless, Moderna's resilience and expansion beyond COVID-related products could help mitigate potential risks.

08.03.2026 - MRNA Stock was up 5.5%

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

08.03.2026 - MRNA Stock was up 6.7%

• Moderna saw a significant rise in its stock price following an increase in price target to $35 from $30 by RBC Capital Markets, while maintaining a "Sector Perform" rating.
• This optimistic forecast signifies the market's confidence in Moderna's potential growth within the biotech sector.
• Analyst revisions, including the raised price target, indicate sustained interest and positivity towards Moderna's pipeline and future developments.
• The general positive sentiment towards Moderna may also be influenced by the broader optimistic outlook on biotech firms and healthcare technology progress, driving investor enthusiasm towards innovative solutions such as mRNA-based therapies.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.